A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?
Public ClinicalTrials.gov record NCT02287025. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Does Physician Education Influence Side Effect Management and Does it Increase Time on Treatment in the Absence of Progression ? A Phase 4 Open-label Trial With Regorafenib in Metastatic Colorectal Cancer
Study identification
- NCT ID
- NCT02287025
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Interventions
- Bayer specialist Other
- Regorafenib (Stivarga, BAY73-4506) Drug
- iPAD application Other
Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 10, 2014
- Primary completion
- Feb 25, 2016
- Completion
- Apr 7, 2016
- Last update posted
- Oct 18, 2017
2014 – 2016
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Anniston | Alabama | 36207 | — |
| Not listed | Anaheim | California | 92801 | — |
| Not listed | Orange | California | 92668 | — |
| Not listed | Lake City | Florida | 32024 | — |
| Not listed | Skokie | Illinois | 60076 | — |
| Not listed | Skokie | Illinois | 60077 | — |
| Not listed | Lafayette | Indiana | 47905 | — |
| Not listed | Columbia | Maryland | 21044 | — |
| Not listed | Fayetteville | North Carolina | 28304 | — |
| Not listed | Canton | Ohio | 44718 | — |
| Not listed | Tulsa | Oklahoma | 74146 | — |
| Not listed | Gettysburg | Pennsylvania | 17325 | — |
| Not listed | Kingsport | Tennessee | 37660 | — |
| Not listed | Houston | Texas | 77024 | — |
| Not listed | Tyler | Texas | 75701 | — |
| Not listed | Bristol | Virginia | 24201 | — |
| Not listed | Portsmouth | Virginia | 23704 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02287025, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 18, 2017 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02287025 live on ClinicalTrials.gov.